|

DXC006 Clinical Trials

1 actively recruiting trial

Also known as: Recombinant Humanized Antibody-drug conjugate

Pipeline

Phase 1: 1

Top Sponsors

  • Hangzhou DAC Biotechnology Co., Ltd.1

Indications

  • Hematological Malignancies1
  • Advanced Solid Tumors1
  • Cancer1

Other1 trial

A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.